BioCardia Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.08
Dividend & YieldN/A$ (N/A)
Beta 1.15
Market capitalization 33.01M
Operating cash flow -10.54M
ESG Scores unknown

Company description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 54k 862k -176k -75k
Total Cashflows From Investing Activities -66k -146k -32k -116k
Net Borrowings 625k 625k 506k
Total Cash From Financing Activities 3.8M 9.82M 28.21M 1.95M
Change To Operating Activities 132k 284k 390k 507k
Issuance Of Stock 4M 10.45M 30.5M 2.01M
Net Income -13.99M -14.71M -15M -12.62M
Change In Cash -7.33M 227k 15.82M -8.54M
Effect Of Exchange Rate
Total Cash From Operating Activities -11.07M -9.45M -12.36M -10.37M
Depreciation 88k 551k 68k 60k
Change To Account Receivables -179k 127k -85k 85k
Other Cashflows From Financing Activities -200k -1.26M -2.63M -59k
Change To Netincome 2.77M 3.3M 2.45M 1.68M
Capital Expenditures -66k -146k -32k -116k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 8.56M 8.56M 8.56M 8.56M
Income Before Tax -13.99M -14.71M -15M -12.62M
Net Income -13.99M -14.71M -15M -12.62M
Selling General Administrative 5.76M 6M 5.86M 5.09M
Gross Profit -8.35M -8.21M -9.67M -7.54M
Ebit -14.1M -14.21M -15.53M -12.63M
Operating Income -14.1M -14.21M -15.53M -12.63M
Interest Expense -112k -112k -3k
Income Tax Expense
Total Revenue 625k 710k 145k 1.01M
Cost Of Revenue 8.97M 8.92M 9.81M 8.56M
Total Other Income ExpenseNet 115k -496k 525k 7k
Net Income From Continuing Ops -13.99M -14.71M -15M -12.62M
Net Income Applicable To Common Shares -13.99M -14.71M -15M -12.62M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 2.62M 5.31M 4.25M 5.34M
Total Stockholder Equity 3.79M 2.37M 19.18M 10.38M
Other Current Liabilities 757k 732k 1.39M 1.53M
Total Assets 6.42M 7.68M 23.42M 15.72M
Common Stock 5k 7k 16k 17k
Other Current Assets
Retained Earnings -86.36M -101.07M -116.07M -128.7M
Treasury Stock
Cash 5.36M 5.58M 21.41M 12.87M
Total Current Liabilities 2.55M 4M 4.25M 3.71M
Other Stockholder Equity
Property, Plant, and Equipment 145k 1.25M 712k 2.06M
Total Current Assets 6.22M 6.38M 22.66M 13.48M
Net Tangible Assets 3.79M 2.37M 19.18M 10.38M
Net Receivables 274k 147k 850k 147k
Accounts Payable 743k 914k 746k 507k


Insider Transactions

Here are the insider transactions of stock shares related to BioCardia Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
ALTMAN PETERPurchase at price 1.86 - 1.87 per share.D2022-11-11Chief Executive Officer4.5k
MCCLUNG DAVIDPurchase at price 2.07 per share.D2022-10-10Chief Financial Officer2k
ALTMAN PETERPurchase at price 1.81 - 1.87 per share.D2022-09-23Chief Executive Officer4.5k
ALTMAN PETERPurchase at price 1.92 per share.D2022-09-21Chief Executive Officer2.75k
ALTMAN PETERPurchase at price 1.46 per share.D2022-06-10Chief Executive Officer4.5k
ALTMAN PETERPurchase at price 1.20 - 1.38 per share.D2022-05-13Chief Executive Officer15k
ALTMAN PETERPurchase at price 1.59 - 1.61 per share.D2022-04-29Chief Executive Officer5k
ALTMAN PETERPurchase at price 1.39 per share.D2022-04-18Chief Executive Officer13.5k
GILLIS EDWARD MStock Award(Grant) at price 0.00 per share.D2022-04-14Officer30.16k
MCCLUNG DAVIDStock Award(Grant) at price 0.00 per share.D2022-04-14Chief Financial Officer50.34k
ALTMAN PETERStock Award(Grant) at price 0.00 per share.D2022-04-14Chief Executive Officer76.73k
ALTMAN PETERPurchase at price 2.20 per share.D2021-11-18Chief Executive Officer5k
ALTMAN PETERPurchase at price 2.94 per share.D2021-08-17Chief Executive Officer3.5k
GILLIS EDWARD MStock Award(Grant) at price 0.00 per share.D2021-04-21Officer9.95k
MCCLUNG DAVIDStock Award(Grant) at price 0.00 per share.D2021-04-21Chief Financial Officer21.37k
ALTMAN PETERStock Award(Grant) at price 0.00 per share.D2021-04-21Chief Executive Officer33.58k
MOYES JAY MStock Award(Grant) at price 0.00 per share.D2021-03-31Director3.46k
KRASNO RICHARD MStock Award(Grant) at price 0.00 per share.D2021-03-31Director3.02k
ZSEBO KRISZTINA MStock Award(Grant) at price 0.00 per share.D2021-03-31Director2.74k
STERTZER SIMON HStock Award(Grant) at price 0.00 per share.D2021-03-31Director and Beneficial Owner of more than 10% of a Class of Security2.3k
BLANK ANDREW SCOTTStock Award(Grant) at price 0.00 per share.D2021-03-31Director4.75k
ALLEN JIM LStock Award(Grant) at price 0.00 per share.D2021-03-31Director2.52k
PFENNIGER RICHARD C JRStock Award(Grant) at price 0.00 per share.D2020-12-31Director5.92k
MOYES JAY MStock Award(Grant) at price 0.00 per share.D2020-12-31Director6.55k
KRASNO RICHARD MStock Award(Grant) at price 0.00 per share.D2020-12-31Director5.53k
ZSEBO KRISZTINA MStock Award(Grant) at price 0.00 per share.D2020-12-31Director244
STERTZER SIMON HStock Award(Grant) at price 0.00 per share.D2020-12-31Director and Beneficial Owner of more than 10% of a Class of Security5.77k
BLANK ANDREW SCOTTStock Award(Grant) at price 0.00 per share.D2020-12-31Director7.64k
ALLEN JIM LStock Award(Grant) at price 0.00 per share.D2020-12-31Director5.53k
ALTMAN PETERPurchase at price 2.37 - 2.49 per share.D2020-12-01Chief Executive Officer4.2k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to BioCardia Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on BioCardia Inc

Here is the result of two systematic investment strategies applied to BioCardia Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on BioCardia Inc

The following chart shows the equity curve of the two systematic investment strategies applied to BioCardia Inc:

BioCardia Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -59.56% on the backtest period.

Performance at glance

Performance

-59.56 %

Latent gain

-1193.05 $

Invested capital

2003.13 $

Annualized return

-14.39 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on BioCardia Inc

This is the result of two momentum investment strategies applied to BioCardia Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on BioCardia Inc

The following chart shows all the entries opened by the momentum investment system on BioCardia Inc:

BioCardia Inc momentum entries
  • The first momentum investment strategy would give -53.9% of return on BioCardia Inc. That represents -2964.23$ of latent gain with 5499.39$ of employed capital.
  • The second momentum investment strategy would give -46.02% of return on BioCardia Inc. That represents -1837.07$ of latent gain with 3991.59$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-53.9 %

Latent gain

-2964.23 $

Invested capital

5499.39 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-46.02 %

Latent gain

-1837.07 $

Invested capital

3991.59 $

Annualized return

-12.57 %

Momentum equity curve on BioCardia Inc

The following chart shows the equity curve of the two momentum strategies applied to BioCardia Inc:

BioCardia Inc momentum equity

Note: the dividends potentially given by BioCardia Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on BioCardia Inc

The following chart shows the employed capital evolution of the two momentum strategies on BioCardia Inc since the beginning:

BioCardia Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on BioCardia Inc

Buy the dip entry openings on BioCardia Inc

BioCardia Inc

The performance achieved by the robo-advisor on BioCardia Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows BioCardia Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of BioCardia Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to BioCardia Inc

The following chart shows the result of the investment strategy applied to BioCardia Inc:

BioCardia Inc

Note: the dividends potentially given by BioCardia Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on BioCardia Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on BioCardia Inc:

BioCardia Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on BioCardia Inc

In this section, I will compare the three previous investment strategies applied to BioCardia Inc.

Equity curve comparison on BioCardia Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

BioCardia Inc investment strategy comparison

Employed capital comparison on BioCardia Inc

BioCardia Inc investment comparison

Performance comparison on BioCardia Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -59.56% -1193.05$ 2003.13$ -14.39%
Momentum 1 quarter -53.9% -2964.23$ 5499.39$ -13.82%
Momentum 2 quarters -46.02% -1837.07$ 3991.59$ -12.57%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-14.39 %

Momentum 1Q

-12.57 %

Momentum 2Q

-12.57 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with BioCardia Inc:

Positive correlations

Most correlated stocks this year

  • BioCardia Inc

  • Most correlated stocks last 3 months

  • BioCardia Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between BioCardia Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of BioCardia Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name BioCardia Inc
    Country United States
    City Sunnyvale
    Address 320 Soquel Way
    Phone 650 226 0120
    Website www.biocardia.com
    FullTime employees 28
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker BCDA
    Market www.nasdaq.com

    BioCardia Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown